CHANGE OF NUMBER OF SHARES AND VOTES IN MOBERG DERMA

The number of shares and votes in Moberg Derma AB (publ) has increased by 1,733,552 to 10,812,572 during November 2012. Therefore, there are in total 10,812,572 shares and votes in the company as of November 30th, 2012.

The increase is a result of a directed share issue of 907,900 shares resolved by the board under an authorization from the annual general meeting 2012, and an issue in kind of 825,652 shares resolved by the board under an authorization from the extraordinary general meeting held November 19th, 2012. Both share issues are made in order to accomplish Moberg Derma’s acquisition of Alterna, LLC.

For additional information contact:
Peter Wolpert, CEO

Mobile: +46 (0)70 – 735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, head of investor relations
Mobile: +46 (0)73 – 355 26 01
Email: magnus.persson@mobergderma.se

About this information
Moberg Derma AB (publ) is required to publish the above information under the Swedish Financial Instruments Trading Act. The information was submitted for publication at 2.00 pm (CET) on November 30th 2012.

About Moberg Derma
Moberg Derma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The Company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Emtrix® and Kaprolac®. Emtrix® (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Derma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.com.

Tags:

About Us

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in more than 800 patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Contacts

Subscribe

Documents & Links